[A differentiated approach to the treatment of normal-pressure glaucoma].
Seventy patients with normal pressure glaucoma (NPG) were treated on the differential basis with respect to a pathogenetic disease type. The suggested complex therapy of the ischemic variation improves both the microcirculation in the optic nerve disk (OND) by administering different-effect drugs in long courses and the systemic hemodynamics (practitioners of needed skills are involved). The use of local antihypertensive drug to reduce the intraocular pressure to an individual tolerable value is important in the treatment of patients with tension-ischemic glaucoma. The process stabilized in 75.8 +/- 3.9% of patients in the main group and in 47 +/- 8.5% of patients in the control group (p < 0.05) after a follow-up of up to 2.5 years.
E G
EG
Grigor'eva
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D015784:Betaxolol / Q000008:administration & dosage / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000627:therapeutic use; D002257:Carbonic Anhydrase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D005500:Follow-Up Studies; D005901:Glaucoma / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000601:surgery; D006439:Hemodynamics; D006801:Humans; D007429:Intraocular Pressure; D009543:Nifedipine / Q000008:administration & dosage / Q000627:therapeutic use; D010431:Pentoxifylline / Q000008:administration & dosage / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D012189:Retrospective Studies; D012307:Risk Factors; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use; D013843:Thiazines / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D013999:Timolol / Q000008:administration & dosage / Q000627:therapeutic use; D014130:Trabeculectomy; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D002257:Carbonic Anhydrase Inhibitors; D010726:Phosphodiesterase Inhibitors; D010975:Platelet Aggregation Inhibitors; D013449:Sulfonamides; D013843:Thiazines; D014665:Vasodilator Agents; D013999:Timolol; C111827:brinzolamide; D009543:Nifedipine; D015784:Betaxolol; D010431:Pentoxifylline